Business Description
Q/C Technologies Inc. is a clinical-stage pharmaceutical company founded in 2014 and based in New York, working to develop new treatments for a range of serious conditions, including autoimmune diseases, epilepsy, pain, and anxiety. Its two lead drug candidates are Isomyosamine, which targets the body's immune and metabolic systems, and Supera-CBD, a lab-made compound derived from cannabidiol. Beyond pharmaceuticals, the company is also building computing technology designed to support artificial intelligence applications. Formerly known as TNF Pharmaceuticals Inc., Q/C Technologies maintains a research partnership with the DADA2 Foundation to study a rare inflammatory disease called DADA2.
